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Fractures of the proximal femur are one of the greatest challenges facing the medical 
community, constituting a heavy socioeconomic burden worldwide. Controversy exists 
regarding the optimal treatment for independent patients with displaced intracapsular 
fractures of the proximal femur. The recognised alternatives are hemiarthroplasty and total 
hip replacement. At present there is no established standard of care, with both types of 
arthroplasty being used in many centres. The principal advantages of total hip replacement 
are a functional benefit over hemiarthroplasty and a reduced risk of revision surgery. The 
principal criticism is the increased risk of dislocation. We believe that an alternative 
acetabular component may reduce the risk of dislocation but still provide the functional 
benefit of total hip replacement in these patients. We therefore propose to investigate the 
dislocation risk of a dual-mobility acetabular component compared with standard 
polyethylene component in total hip replacement for independent patients with displaced 
intracapsular fractures of the proximal femur within the framework of the larger WHiTE 
(Warwick Hip Trauma Evaluation) Comprehensive Cohort Study.
Cite this article: Bone Joint Res 2013;2:210–13.
Introduction
Fracture of the proximal femur is one of the
greatest challenges facing the medical com-
munity. In 1990, a global incidence of
1.31 million was reported, associated with
740 000 deaths.1 Proximal femoral fractures
constitute a heavy socioeconomic burden
worldwide. The cost of this clinical problem is
estimated at 1.75 million disability adjusted
life years lost, and 1.4% of the total healthcare
burden in established market economies.1 
The accepted treatment of a displaced
intracapsular fracture is an arthroplasty.2 This
includes both hemiarthroplasty (HA), in
which the proximal femur is replaced, and
total hip replacement (THR), through which
both the femur and acetabulum are replaced.
Recently, an increasing body of evidence has
demonstrated that for selected, compara-
tively healthy and independent patients, THR
offers functional benefit and a reduced risk of
revision surgery over HA.3
The principal clinical concern with THR is
the risk of dislocation. Dislocation often
requires inpatient admission for closed
reduction and may require revision surgery
with its consequent risks. Alternative
acetabular components are available with
dual-mobility bearing surfaces (THR-DM)
that may reduce the risk of dislocation, yet
provide the functional benefit of standard
THR.4
The aim of this trial is to investigate the dis-
location risk of a dual-mobility acetabular
component compared with a standard poly-
ethylene component in THR for independent
patients with displaced intracapsular frac-
tures of the proximal femur.
Patients and Methods
Study design. This will be a single-centre,
multi-surgeon, parallel, two-arm, standard-
of-care randomised controlled pilot study. It
will be embedded within the WHiTE Compre-
hensive Cohort Study.5 The study will include
a two-way superiority comparison between
standard THR and THR-DM.
Ethical approval. This study has been
reviewed by the National Research Ethics Ser-
vice Committee – West Midlands & Coventry
(13/WM/0110). The study was given ethical
approval on 1 May 2013. The research will be
carried out in compliance with the Helsinki
Declaration.
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Study registration. This study has been registered with
the International Standard Randomised Controlled Trial
Number Register (ISRCTN90544391).
Study participants. All patients aged ≥ 60 years with an
AO/OTA type B3 fracture6 of the proximal femur are eligi-
ble for inclusion in this study. Patients will be excluded if
they have chronic cognitive impairment, or in the opinion
of the consultant trauma surgeon the patient will not
benefit from THR, or are medically unfit for an operation
and are treated non-operatively.
Recruitment. Pre-enrolment eligibility checks will be car-
ried out to ensure that participants are not enrolled in
error, and informed written consent will be obtained prior
to enrolment. Confirmation of these checks will be carried
out by the Chief Investigator, or persons designated by the
Chief Investigator, before enrolment. Inclusion of the par-
ticipant in the study will be flagged on their clinical notes
by means of a study sticker. An annotation will be made in
the participant’s medical notes to reflect that the patient
has consented to take part in the trial. A copy of the patient
information material as well as a copy of the signed con-
sent form will be filed in the patient’s notes. 
Timeline. Recruitment is planned to commence in May
2013 and last for one year in the first instance.
Consent. The large majority of patients with fracture of
the proximal femur are a clinical priority for urgent oper-
ative care. They will undergo surgery on the next avail-
able trauma operating list. All patients with a fracture of
the proximal femur are in pain and have received opiate
analgesia. It is therefore understandable that patients find
the initial period of their treatment in hospital confusing
and disorientating. Similarly, patients’ next of kin, carers
and friends are anxious at this time and may also have dif-
ficulty in weighing the large amounts of information that
they are given about the injury and plan for treatment.
In this emergency situation the focus is on obtaining
consent for surgery (where possible) and informing the
patient and any next of kin about immediate clinical care.
It is not possible for the patient/consultee to review trial
documentation, weigh the information and communi-
cate an informed decision about whether they would
wish to participate.
Conducting research in this ‘emergency setting’ is regu-
lated by the Mental Capacity Act 2005 (MCA).7 As patients
are likely to lack capacity as described above, and because
of the urgent nature of the treatment limiting access to and
appropriate discussion with personal consultees, we pro-
pose to act in accordance with section 32, subsection 9b of
the MCA following a process approved by the relevant
research ethics committee. Those patients who have sur-
gery on the next available trauma operating list enter the
study under presumed consent; we will not obtain con-
sent prior to surgery but will endeavour to inform an
appropriate consultee. Where a Personal Consultee is avail-
able, they will be provided with the study information. The
Personal Consultee will be given the opportunity to ask
questions and discuss the study after which their oral
agreement will be recorded.
Due to the urgent nature of the treatment limiting
access to and appropriate discussion with Personal Con-
sultees, we will act in accordance with section 32 subsec-
tion 9b of the MCA. Where a Personal Consultee is not
available then a Nominated Consultee will be identified to
advise the research team. The Nominated Consultee will
be the patient’s treating Trauma and Orthopaedic Sur-
geon. If that surgeon is a member of the research team,
another independent surgeon will be identified.
At the first appropriate time when the patient has
regained capacity (this will usually be on the first day after
surgery) the research associate will provide the participant
with all of the study information. The participant will be
given the opportunity to ask questions and discuss the
study with their family and carers. They will then be asked
to provide written consent for continuation in the study.
Rarely, some patients may be able to consent before
their operation, namely those whose surgery has been
delayed for clinical reasons. These patients will be
approached by the research team before their operation
for consent to participate in the study. Some patients,
whose surgery has been delayed, may still not have
capacity, e.g. those who are acutely confused. If the clin-
ical team in charge of that patients care do not think that
the patient is able to provide clinical consent for their
operation, then the research team will approach a con-
sultee for agreement that the patient participate in the
study. The patient themselves will be approached for con-
sent as soon as the clinical team deem that they have
regained capacity following their operation.
For participants who do not regain capacity or lack capac-
ity, reasonable efforts will be made to identify a Personal
Consultee as described in the Mental Capacity Act 2005. If
no Personal Consultee can be identified then a Nominated
Consultee will be identified to advise the research team. 
At all times the Chief Investigator will act in accordance
with the patients’ best interests.
Best efforts will be made to involve participants who,
temporarily or permanently, lack capacity in the decision
to be involved in the study. The clinical team will make a
judgement about the amount and complexity of the
information that the participant is able to understand and
retain on an individual basis. Appropriate information will
be communicated to the participant and updated as their
understanding changes.
Any new information that arises during the trial that
may affect participants’ willingness to take part will be
reviewed by the Trial Steering Committee; if necessary
this will be communicated to all participants. A revised
consent form will be completed if necessary.
Responsibility for recording and dating both oral and
written informed consent or agreement will be with the
investigator, or persons designated by the investigator,
who conducted the informed consent discussion.
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Post-recruitment withdrawals and exclusions. Partic-
ipants may withdraw from the study at any time without
prejudice. The General Practitioners of those participants
who are ‘lost to follow-up’ will be contacted in order to
attempt to complete the follow-up. Participants may be
withdrawn from the study at the discretion of the Chief
Investigator due to safety concerns.
Treatment allocation
Sequence generation. The allocation sequence will be
generated randomly to achieve a 1:1 ratio using blocks of
variable sizes.
Allocation concealment. The allocation will be deter-
mined using secure, online randomisation via a distant
computer generated system administered by University
of York (York, United Kingdom).
Allocation implementation. Participants will be enrolled
by the trial research associates. Participants will be
assigned to their treatment allocation prior to the time of
surgery by accessing the online randomisation pro-
gramme. This will allow for treatment allocation to be
implemented outside of working hours.
Blinding. Participants will be blinded to the treatment
allocation. The operating surgeon will not be blinded to
the allocation. All clinical outcomes will be assessed by
blinded assessors. Patients will be kept blinded until the
completion of the trial when the blinding is broken. There
will be no formal analysis of the success of the blinding.
Study treatments. Pre-operative assessment, anaesthetic
technique and post-operative rehabililtation will be iden-
tical to all other participants recruited into the larger
WHiTE Comprehensive Cohort Study.5
Surgical intervention
Participants who can tolerate penicillins will receive 1 g
flucloxacillin and 3 mg/kg to 5 mg/kg gentamicin at
induction as an intravenous (IV) infusion over 15 to 30
minutes. Penicillin-sensitive participants will receive tei-
coplanin 600 mg, or 800 mg if body mass exceeds 80
kg, as an IV bolus and 3 mg/kg to 5 mg/kg gentamicin as
an IV infusion over 15 to 30 minutes. Those who have a
positive screen for methicillin-resistant Staphylococcus
aureus (MRSA) will be given the same prophylaxis as
those who are penicillin-sensitive.
Participants will be positioned in the lateral position. The
operating surgeon will perform their preferred approach.
The hip will be dislocated and the head excised. Partici-
pants will be randomly allocated to one of two groups:
1) standard bearing THR; or 2) dual-bearing THR.
Group 1: Standard bearing THR. The approach, implant
and operative technique employed will be at the discre-
tion of the operating surgeon.
Group 2: Dual-bearing THR. The approach, femoral
implant and operative technique employed will be at the
discretion of the operating surgeon. An uncemented
Novae dual-mobility acetabular component (SERF
Dedienne Sante, Lyon, France) will be implanted in accor-
dance with the manufacturer’s operative guide.
Follow-up
Schedule. Participant outcomes will be assessed at base-
line (pre-injury status recorded upon admission to hospi-
tal) and at four, 16 and 52 weeks.
Measures of clinical effectiveness. The primary out-
come will be the rate of dislocation. Secondary out-
comes will include the EuroQol 5-Dimension (EQ-5D)8
measure of general health, the ICEpop CAPability mea-
sure for Older people (ICECAP(O)),9 the Oxford hip
score (OHS),10 mortality risk, revision risk and cause,
and length of hospital stay.
Health economic measures. The patient-recorded out-
come data will be combined with mortality data
extracted from the National Hip Fracture Database
(NHFD) to estimate a quality-adjusted life year (QALY)
profile for each patient. This will allow us to estimate the
production of health associated with surgical procedures
and treatment pathways for each participant.
Power and sample size
The data to adequately inform a sample size calculation
for this study are not available. The limited available evi-
dence suggests a likely dislocation risk of between 5%
and 7% in the standard THR group3 and 1% in the DM-
THR group.4 Based upon the NHFD report,11 approxi-
mately 100 independent patients with AO/OTA B36 frac-
tures of the proximal femur are treated operatively per
year at University Hospitals Coventry and Warwickshire
NHS Trust. The mortality of these patients was 1% at
120 days following the index fracture. Given these likely
event risks, a pragmatic sample recruited over one year
should provide adequate data to inform a subsequent
sample size calculation for a definitive trial.
Statistical analysis
Analysis of clinical effectiveness. The primary outcome
measure, the proportion of patients sustaining a disloca-
tion of their arthroplasty within one year of the index frac-
ture, will be analysed using a chi-squared test for
differences between standard THR (control) and THR-DM
(test) on an intention-to-treat basis. Treatments will be
considered to differ significantly if p-values are < 0.05
(5% level). Similarly, chi-squared tests will be used to
assess the significance of observed differences for the sec-
ondary proportional outcome measures. If the numbers
in the contingency tables are small (cells with values < 10)
then Fisher’s exact test will be used in preference to the
chi-squared test. In addition to the main analysis, that will
report treatment group effects for the primary outcome
measure, a subsidiary analysis will use a multiple linear
regression model to investigate the relationship between
each patient’s EQ-5D score at 12 months and the treat-
ment arm, age, gender and dementia for each patient.
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Estimates, and 95% confidence intervals, from the regres-
sion model, and unadjusted results from t-tests will be
reported and inferences made on the significance of the
treatment effect. All analyses will be based upon an inten-
tion-to-treat analysis so missing data due to protocol vio-
lations will not be relevant. The primary outcome
measure in this study has been chosen in order to limit the
possibility of losing data from failed participant follow-
up. The primary measure can be sourced from the
patient, relative, General Practitioner or NHFD.
Analysis of cost effectiveness. The economic evaluation
will estimate the incremental cost effectiveness of THR-DM
and standard THR. The primary outcome will be the qual-
ity adjusted life year gained. Health-related quality of life
will be estimated using the EQ-5D score. These data will be
collected at baseline (pre-injury status), four, 12 and
52 weeks post-injury. Hospital based resource use will be
extracted form participants’ clinical record. Unit cost data
will be obtained from University Hospitals Coventry and
Warwickshire NHS Trust. A within trial evaluation will com-
pare the outcomes and cost up to one year post-injury
using trial data and index hospital episode data.
Analysis of adverse events. The number and temporal
pattern of adverse events will be investigated to assess if
these differ between treatment groups. 
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